ProShares UltraShort NASDAQ Biotechnology
5 hedge funds and large institutions have $691K invested in ProShares UltraShort NASDAQ Biotechnology in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
3.82% less ownership
Funds ownership: 8.73% → 4.91% (-3.8%)
17% less funds holding
Funds holding: 6 → 5 (-1)
45% less capital invested
Capital invested by funds: $1.26M → $691K (-$569K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$260K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$43K |
| 3 |
Morgan Stanley
New York
|
+$3.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
-$495K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$388K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$41.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $397K | +$43K | +1,099 | +12% |
|
|
OMC
2
Old Mission Capital
Chicago,
Illinois
| $266K | +$260K | +6,629 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $18K | -$41.9K | -1,070 | -71% |
|
|
4
Morgan Stanley
New York
| $8K | +$3.92K | +100 | +110% |
|
5
Citigroup
New York
| $2K | – | – | – |
|
|
6
IMC Chicago
Chicago,
Illinois
| – | -$495K | -13,730 | Closed |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$388K | -10,753 | Closed |
|
BIS Hedge Fund Activity: Q4 2021 in Review
5 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2021, worth a combined $691K — down 45% from $1.26M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Old Mission Capital, opening a new position worth an estimated $260K. The largest seller was IMC Chicago, exiting entirely with an estimated $495K sold.
- 5 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2021, down from 6 in Q3 2021.
- Funds reported $691K of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2021, down 45% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2021 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2021 was Old Mission Capital, an estimated $260K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2021 was IMC Chicago, an estimated $495K sold.
Based on aggregated 13F filings for Q4 2021.